Current biomarkers for tumor immunotherapy mainly include co-positive score (CPS) for PD-L1 expression, microsatellite instability/defective mismatch repair (MSI/dMMR) status and tumor mutation burden (TMB) [2]. Here, CD274 is linked to neoplasm.